Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity

Rafael Ribeiro Almeida1,2, Raquel de Souza Vieira1,2, Angela Castoldi1, Fernanda Fernandes Terra1, Amanda Campelo L. Melo1, Maria Cecília Campos Canesso3, Luisa Lemos3, Marcella Cipelli1, Nisha Rana4, Meire Joshiy Hiyane1, Erika L. Pearce4, Flaviano dos Santos Martins5, Ana Maria Caetano de Faria3 and Niels Olsen Saraiva Câmara1

BACKGROUND: Host–microbiota interactions shape T-cell differentiation and promote tumour immunity. Although IL-9-producing T cells have been described as potent antitumour effectors, their role in microbiota-mediated tumour control remains unclear.

METHODS: We analysed the impact of the intestinal microbiota on the differentiation of colonic lamina propria IL-9-producing T cells in germ-free and dysbiotic mice. Systemic effects of the intestinal microbiota on IL-9-producing T cells and the antitumour role of IL-9 were analysed in a model of melanoma-challenged dysbiotic mice.

RESULTS: We show that germ-free mice have lower frequency of colonic lamina propria IL-9-producing T cells when compared with conventional mice, and that intestinal microbiota reconstitution restores cell frequencies. Long-term antibiotic treatment promotes host dysbiosis, diminishes intestinal IL-4 and TGF-β gene expression, decreases the frequency of colonic lamina propria IL-9-producing T cells, increases the susceptibility to tumour development and reduces the frequency of IL-9-producing T cells in the tumour microenvironment. Faecal transplant restores intestinal microbiota diversity, and the frequency of IL-9-producing T cells in the lungs of dysbiotic animals, restraining tumour burden. Finally, recombinant IL-9 injection enhances tumour control in dysbiotic mice.

CONCLUSIONS: Host–microbiota interactions are required for adequate differentiation and antitumour function of IL-9-producing T cells.

British Journal of Cancer (2020) 123:534–541; https://doi.org/10.1038/s41416-020-0915-6

BACKGROUND
Multicellular organisms coexist with a symbiotic commensal microbiota. A complex community of bacteria, fungi, protozoa and viruses colonises humans, especially the gut, and plays a fundamental role in controlling host physiology.1 The crosstalk between the intestinal microbiota and the immune system allows tolerance of commensal bacteria and oral food antigens, and also enables recognition and control of opportunistic bacteria, preventing host invasion and infection. Along with local effects, the intestinal microbiota also have a broad range, shaping innate and adaptive immunities at multiple levels.2

Studies performed in germ-free (GF) mice, raised in the absence of live microbes, have revealed that ablation of the microbiota results in severe defects in the immune system, leading to altered immunoglobulin A (IgA) secretion, absent intestinal mucous layer, small Peyer’s patches and underdeveloped mesenteric lymph nodes (mLNs).3–5 On the other hand, different experimental approaches have demonstrated that manipulation of the intestinal microbiota may result in local and systemic immune restoration. For instance, full intestinal microbial colonisation of GF mice was shown to drive expansion of peritoneal IL-17-producing γδ T cells,5 while Bacteroides fragilis colonisation corrected systemic T-cell deficiencies and Th1/Th2 imbalances in a PSA-dependent mechanism.6 Segmentated filamentous bacteria (SFB) and microbiota-derived ATP were shown to restore lamina propria Th17 cells in GF animals,7–9 while colonisation with B. fragilis and indigenous Clostridium species induced colonic regulatory T-cell (Treg) differentiation via PSA/TLR2 engagement, and by promoting a transforming growth factor-β (TGF-β)-rich environment.10–12

The intestinal microbiota composition is fine-tuned and subjected to different perturbations that may result in a less-diverse and less-stable architecture known as dysbiosis, which is frequently associated with impaired local and systemic immune responses.13–15 GF mice colonised with intestinal microbiota from animals with inflammation-associated colorectal cancer were shown to be more susceptible to tumorigenesis,16 and administration of Fusobacterium nucleatum was shown to promote a proinflammatory microenvironment, and to potentiate intestinal tumorigenesis in specific pathogen-free (SPF) mice.17 Systemically, it was demonstrated that a dramatic reduction of gut commensals via broad-spectrum antibiotic treatment resulted in increased susceptibility to melanoma and Lewis carcinoma development in...
mice, negatively impacting IL-17-producing γδ T cells. More recently, antibiotic-induced dysbiosis was shown to enhance distal tumour progression by altering host cytokine levels and endothelial adhesion molecules, resulting in a defective recruitment of effector CD8+ T cells into the tumour microenvironment. Many other studies have also indicated a fundamental role of the microbiota in regulating responses to cancer therapies, such as CpG-based immunotherapy, platinum-based chemotherapy and checkpoint inhibitors anti-CTLA4 and anti-PD1/PDL-1.

Although host–microbiota interactions have been described to regulate the differentiation and function of many effector and regulatory T cells, contributing to homoeostasis and tumour immunity, no study has addressed whether these interactions would have an impact on IL-9-producing CD4+ (Th9) and CD8+ (Tc9) T cells. Th9 and Tc9 cells share developmental pathways with both Th2 and Treg cells, being differentiated in response to IL-4 and TGF-β. These cells are mainly characterised by IL-9 production, and also by the expression of the transcription factors PU.1, STAT6 and IRF4. While Th9 cells were shown to be more efficient than Th1 and Th17 cells in preventing tumour progression, to promote IL-9-dependent antitumour immunity, and to have direct cytotoxic effects on tumour cells, Th9 and Tc9 cells were shown to be superior effectors than type-I cytokine Tc1 cells for adoptive cancer immunotherapy, and to also depend on IL-9 for their antitumour response. Here, we investigated the role of the intestinal microbiota in promoting the development of lamina propria Th9 and Tc9 cells by reconstituting germ-free mice with faecal microbiota from conventional mice. We also performed long-term antibiotic treatment in specific pathogen-free mice to evaluate the impact of host dysbiosis on IL-9-producing T cells in the colonic lamina propria, and in the context of extraintestinal tumour immunity. Taken together, our results indicate that host–microbiota interactions drive differentiation and antitumour function of IL-9-producing T cells.

**METHODS**

Germ-free mice and conventionalisation

Six to 8-week-old male conventional (CV), germ-free (GF) and germ-free conventionalised (CVN) Swiss mice were used for analysis of colonic lamina propria cells at the Federal University of Minas Gerais in accordance with the National Institutes of Health guide for the care and use of Laboratory animals and the guidelines of the Institutional Ethics Committee. Animals were housed in groups of up to five per cage in a light- and temperature-controlled room (12-h light/dark cycles, 21 ± 2°C) with free access to food and water. Conventionalisation was achieved by oral gavage of PBS-homogenised faecal samples from the large intestine of CV mice to GF mice, which were also left in co-housing with CV mice for 21 days prior to immunological analysis. Animals were euthanised with an overdose of isoflurane, and experiments were performed after trained personnel recognised cessation of vital signs. Three independent experiments were performed with 8–10 animals per group.

**Microbiota analysis**

Microbiota depletion was evaluated by culturing faecal samples in fluid thioglycollate media (Neogen, Lansing, MI, USA) for 3 days in a microbiological incubator at 37°C and 180 rpm. Alternatively, bacterial load in faecal samples was determined by 16S RNA quantification, as previously described. For metagenomic analysis, DNA was extracted from faecal samples using the QIAamp DNA Mini Stool kit (Qiagen, Germantown, MD, USA) and quantified. The 16S rRNA gene amplification and sequencing were performed according to Illumina MiSeq 16S Metagenomic Sequencing Library Preparation protocol at CEFAP/ICB-USP. Amplicons were multiplexed using the Nextera XT Index kit. The quality of libraries was assessed using Bioanalyzer (Agilent, Santa Clara, CA, USA) and quantified using Qubit (Thermo Fisher, Waltham, MA, USA). Sequence analysis was performed using the Qiime package version 1.9.1 and Qiime2.

**B16F10 culture and injection**

B16F10 cells (ATCC) were cultured in RPMI (Thermo Fisher) with 10% FBS (Thermo Fisher) at 37°C and 5% CO2. C57BL/6 mice were injected with 5 × 104 B16F10 cells through the tail vein, and tumour foci number was determined in the lungs 14 days after injection. Animals were euthanised as previously described. Three independent experiments were performed with 10–12 animals per group.

**IL-9 treatment**

Antibiotic-treated mice were intraperitoneally injected either with 250 ng of recombinant IL-9 (R&D Systems, Minneapolis, MN, USA) diluted in 200 µl of PBS or PBS only at the day of B16F10 cells’ injection and every other day throughout tumour development. Animals were euthanised as previously described. Two independent experiments were performed with 6–8 animals per group.

**Isolation of lamina propria cells**

Colonial lamina propria cells were isolated as detailed. Briefly, animals were euthanised as previously described, and the large intestine was dissected, longitudinally opened, washed with PBS and cut into small pieces. Tissue fragments were placed in 50 ml dishes and washed three times in calcium- and magnesium-free HBSS containing 1 mM dl-dithiothreitol (DTT, Sigma-Aldrich, Irvine, UK) for 30 min. Supernatants were discarded. After that, tissue fragments were incubated with 100 µl/mL of collagenase II (Sigma-Aldrich) for 60 min at 37°C on a shaker. Supernatants were passed through a 70-µm cell strainer (Falcon, Coming, NY, USA), and then resuspended in R-10 medium (RPMI with 10% FBS, 2 mM L-glutamine (Thermo Fisher), 1 mM sodium pyruvate (Thermo Fisher), 1% non-essential amino acids (Thermo Fisher), 1% Pen/Strep, 1% vitamin solution (Thermo Fisher) and 5 x 10^-5 M 2-mercaptoethanol) for further analysis.

**Isolation of lung cells**

Mice were euthanised as previously described, and lungs collected, washed in ice-cold PBS, cut into small pieces and incubated in R-10 medium with 0.5 mg/ml collagenase IV (Thermo Fisher) and 30 µg/ml DNase at 37°C for 45 min and 180 rpm. Digested tissues were passed through 100-µm cell strainers and
Host microbiota play a key role in the development of intestinal IL-9-producing T cells. Colon and lung samples were stained with antibodies against CD3, CD8, CD4, IFN-γ, IL-9, and TGF-β to determine the frequency of IL-9-producing T cells. Flow cytometry analysis showed a significantly lower frequency of Th9 and Tc9 cells in ABX-treated animals (data not shown). We found that TGF-β and IL-4 gene expression, key cytokines for Th9 and Tc9 differentiation, was significantly impaired in colons of ABX-treated animals (Fig. 2c, d, respectively). Flow cytometry analysis showed a significantly lower frequency of Th9 and Tc9 cells in the colonic lamina propria of ABX-treated animals (Fig. 2e-g). Taken together, these results indicate that the host microbiota play a key role in the differentiation of IL-9-producing T cells, and that the mechanism may rely on TGF-β and IL-4 expression.

Antibiotic treatment negatively modulates IL-9-producing T cells in tumour microenvironment and enhances tumour development. Given the fact that the host microbiota were important for the differentiation of both Th9 and Tc9 cells in the colonic lamina propria, we next sought to evaluate whether a long-term antibiotic treatment would impair IL-9-producing T cells in an extraintestinal tumour model. To address this question, we injected B16F10 cells in ABX-treated and -untreated animals through the tail vein in order to promote tumour growth in the lungs. We demonstrated that ABX-treated mice were more susceptible to tumour development than controls, as shown by a higher number of lung foci (Fig. 3a). We observed a significantly lower frequency of Th9 and Tc9 cells (Fig. 3b, c) in the lungs of ABX-treated animals. In contrast, no difference in the frequency of IL-9-producing non-T cells was found (Fig. 3d). Metagenomic analysis showed that antibiotic treatment reduced microbiota diversity before injection of B16F10 cells, which was maintained throughout tumour development (Fig. 3e). Overall, these data indicate that antibiotic-mediated dysbiosis negatively modulates IL-9-producing T cells.
in the tumour microenvironment, and that antibiotic-treated animals are more susceptible to tumour development.

Faecal transplant restores IL-9-producing T cells in the tumour microenvironment and protects mice from tumour development

To confirm the role of the host microbiota in modulating Th9 and Tc9 cells in the tumour microenvironment, PBS-homogenised faecal samples from control animals were orally given to ABX-treated mice to re-establish microbiota composition before injection of B16F10 cells. We found that faecal transplants significantly impaired tumour burden in the lungs, maintaining the number of foci close to that observed in control animals (Fig. 4a). Flow cytometry analysis revealed that the frequency of both IL-9-producing CD4+ (f) and CD8+(g) T cells was restored to that observed in control animals (Fig. 4b, c, respectively). Microbiota recolonisation was confirmed by metagenomic analysis of faecal samples (Fig. 4d), and we observed that antibiotic treatment significantly reduced microbiota diversity, while faecal transplanted animals were restored to that observed in control animals (Fig. 4e). Control and faecal-transplanted animals showed similar microbiota profiles, which were different from ABX-treated animals (Fig. 4f). These results reinforced our data suggesting that the host microbiota have an important role in both modulating the frequency of Th9 and Tc9 cells into the tumour microenvironment, and contributing to protection against tumour development.

IL-9 treatment improves tumour control in dysbiotic animals

The previous reports showing anti-tumoural properties of Th9 and Tc9 cells allied to our results demonstrating no difference in the frequency of IL-9-producing non-T cells in the lungs of ABX-treated mice raised the question whether IL-9 treatment would be sufficient to improve tumour control in those animals as compensation for the lower number of Th9 and Tc9 cells. We therefore injected either recombinant IL-9 or PBS in ABX-treated mice throughout tumour development, and found enhanced tumour control in IL-9-treated animals, as shown by a lower number of lung foci compared with animals treated with PBS (Fig. 5a). We also evaluated cells that have been described as important players in Th9-mediated anti-tumour immunity, and observed that ABX-treated animals presented lower frequency of IFN-γ-producing CD8 + T cells (Fig. 5b) and mast cells (Fig. 5c) in the lungs, which was not improved upon IL-9 treatment (Fig. 5b, c). Therefore, these data indicate that IL-9 contributes to microbiota-mediated control of tumours by a mechanism that may not rely on recruitment of
Host dysbiosis negatively impacts IL-9-producing T-cell differentiation... RR Almeida et al.

**DISCUSSION**

In this study, we demonstrated that the host microbiota play a key role in the differentiation of Th9 and Tc9 cells by showing that germ-free mice have a lower frequency of both cells in the colonic lamina propria when compared with conventional mice, and that faecal transplant followed by co-housing is sufficient to restore cell frequencies. We demonstrated that long-term antibiotic treatment promotes host dysbiosis, diminishes intestinal IL-4 and TGF-β gene expression, decreases the frequency of colonic lamina propria Th9 and Tc9 cells, increases the susceptibility to tumour development and reduces the frequency of Th9 and Tc9 cells in the tumour microenvironment. We found that faecal transplant is sufficient to restore intestinal microbiota diversity and the frequency of IL-9-producing T cells in the lungs of antibiotic-treated animals, restraining tumour burden. Finally, we demonstrated that recombinant IL-9 injection results in enhanced tumour control in dysbiotic mice.

Many studies indicate that host–microbiota interactions contribute to local and systemic T-cell differentiation and function. However, no study had addressed the impact of these interactions on IL-9-producing T cells. We have recently shown that the microbiota-derived short-chain fatty acid (SCFA) butyrate suppresses Th9 differentiation both in vitro and in vivo, impairing lung inflammation. Here, we have demonstrated that Swiss germ-free mice have significantly lower colonic lamina propria Th9 and Tc9 cells when compared with conventional animals, and that intestinal microbiota reconstitution is sufficient to restore cell frequencies. We also found that antibiotic-treated C57BL6 mice present a lower frequency of colonic lamina propria Th9 and Tc9 cells when compared with controls, indicating that host–microbiota interactions are important for the differentiation of these cells, independently of the studied model. Although our previous work and the present results seem contrasting, as the intestinal microbiota are responsible for SCFA production, we believe that a delicate balance between microorganisms and their products is necessary to fully modulate T-cell differentiation and function in different biological conditions.

A previous work has suggested that the host microbiota modulate tumour-immune surveillance in the lungs through an IL-17-producing γδ T-cell-dependent mechanism. A lower number of γδ CD4+ and CD8+ T cells was also observed in the lungs of antibiotic-treated animals, although no further characterisation of T-cell subtypes and their contributions to tumour immunity was performed. Given the increasing evidence that the host microbiota and IL-9-producing T cells modulate tumour progression, we sought to evaluate whether Th9 and Tc9 cells would be among the players of microbiota-mediated protection against tumour development. Our results indicate that antibiotic-induced dysbiosis negatively impacts Th9 and Tc9 cells in the lungs of tumour-challenged mice, indicating that IL-9-producing T cells may pose a significant contribution to microbiota-mediated tumour-immune surveillance. We believe that low expression of IL-4 and TGF-β in dysbiotic animals may have contributed to the defective Th9 and Tc9 differentiation, as these cytokines have a central role in the differentiation of IL-9-producing T cells.

As previously observed, dysbiotic mice were more susceptible to tumour development. We also demonstrated that faecal transplant was sufficient to restore intestinal microbiota diversity and lung-infiltrating Th9 and Tc9 cells, and to impair tumour burden. Although we cannot rule out a contribution of the lung microbiota in the differentiation of Th9 and Tc9 cells, our results with faecal transplant suggest that the intestinal microbiota may...
have had a major impact. The fact that the metronidazole function depends on anaerobic bacteria, and that neomycin/vancomycin-aerosolised mice present significant reduction rather than an increase of melanoma development in the lungs, also supports our hypothesis of a systemic effect of the intestinal microbiota on lung infiltrating antitumour Th9 and Tc9 cells.

To further investigate the effects of Th9 and Tc9 cells in our model, we systemically injected recombinant IL-9 in dysbiotic animals, and found that it could partially protect against tumour burden. Systemic IL-17 injection has also been shown to impair melanoma development in the lungs of dysbiotic animals, suggesting that other cell types may be involved in tumour control. Although Th9 and Tc9 cells may exert direct effects on tumour cells and produce other cytokines, it is well-established that IL-9 has an important contribution to their antitumour immunity. We understand that additional studies regarding T-cell transfer are necessary to confirm the antitumour role of Th9 and Tc9 cells in dysbiotic animals, but our hypothesis is still supported by the fact that IL-9-producing non-T cells were unchanged in the lungs of dysbiotic tumour-challenged mice, indicating that T lymphocytes are probably the main source of IL-9 antitumour effects in our model.

Searching for a mechanism underlying IL-9-mediated protection against tumour burden in dysbiotic animals, we evaluated lung-infiltrating IFN-γ-producing CD8+ T cells and mast cells, and found that dysbiotic tumour-challenged animals had a lower...
frequency of both cells when compared with controls, although it was not improved upon IL-9 treatment. Contrasting information suggests that Th9/IL-9-protective effects rely on the recruitment of either CD8+ T cells or mast cells into the tumour microenvironment.30,31 Here, we found that IL-9 may promote antitumour immunity through a different mechanism when in the context of dysbiosis. For instance, recent data indicate that dysbiosis impairs TNF production, expression of endothelial adhesion molecules and the consequent recruitment of protective IFN-γ-producing CD8+ T cells into the tumour microenvironment,19 which could partially support our findings. It is also possible that other cell types may have exerted antitumour effects in dysbiotic animals upon IL-9 treatment, and that activation rather than recruitment of mast cells is an important factor.43

Dysbiosis has been associated not only with poor intrinsic antitumour immunity, but also with lack of efficacy of different therapies, particularly checkpoint inhibitors, both in animal models and human subjects.32–35 Therefore, improved understanding of how microbiota modulate tumour progression is urgently needed so that better clinical outcomes can be reached. Our study brings an important contribution to the field by demonstrating that dysbiosis affects important players in tumour immunity, such as IL-9-producing T cells, and that these cells should be carefully considered in further studies regarding the impacts of the host microbiota on cancer immunology and therapy.

ACKNOWLEDGEMENTS
The authors would like to thank the animal facility of the Biomedical Science Institute for proving animals used in this study. We also thank Research Support Facilities Center (CEFAP-USP) for flow cytometry support.

AUTHOR CONTRIBUTIONS
R.R.A. conceived the study, designed and performed the experiments and analysed the data. R.S.V., A.C., F.F.T., A.C.M., M.C.C., L.L., M.C. and M.I.H. performed experiments, acquired and analysed the data. N.R. and E.L.P. analysed the data. F.S.M. and A.M.C.F. analysed the data and provided resources. N.O.S.C. provided resources, supervised the study and reviewed the paper. The final version of the paper was approved by all the authors.

ADDITIONAL INFORMATION
Ethics approval and consent to participate All animal experiments were performed in accordance with the National Institutes of Health guide for the care

and use of Laboratory animals, and with the guidelines of the Ethics committee of the Federal University of Minas Gerais and University of São Paulo, under protocol number 2015/006.

Consent to publish Not applicable.

Data availability The data sets generated and analysed during this study are not publicly available, but available from the corresponding author on reasonable request.

Competing interests The authors declare no competing interests.

Funding information This research was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP 2017/02564-7), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), financial code 001. Rafael Almeida is a recipient of a FAPESP scholarship 2015/13817-0.

Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

REFERENCES
1. Ley, R. E., Peterson, D. A. & Gordon, J. I. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 124, 837–848 (2006).
2. Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
3. Johansson, M. E. V., Jakobsson, H. E., Holmen-Larsson, J., Schutte, A., Ermund, A., Rodriguez-Pineiro, A. M. et al. Normalization of host intestinal mucus layers requires long-term microbial colonization. Cell Host Microbe 18, 582–592 (2015).
4. Spijker, M., Merkler, D. & Tjokrovski M. The immune system bridges the gut microbiota with systemic energy homeostasis: focus on TLRs, mucosal barrier, and SCFAs. Front. Immunol. 8, 1333 (2017).
5. Duan, J., Chung, H., Troy, E. & Kasper, D. L. Microbial colonization drives expansion of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. Cell Host Microbe 7, 140–150 (2010).
6. Mazmanian, S. K., Liu, C. H., Tzianabos, A. O. & Kasper, D. L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 122, 107–118 (2005).
7. Ivanov, I. I., Frutos, R. D., Mannel, N., Yoshinaga, K., Rifkin, D. B., Sartor, R. B. et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4, 337–349 (2008).
Host dysbiosis negatively impacts IL-9-producing T-cell differentiation... 

RR Almeida et al.